Phase 2 Startnegative~month

Phase 2 Start: A Phase II Study of Nivolumab Plus Relatlimab 360 mg/360 mg and Gemcitabine/Cisplatin as First-Line

GHRS overview →Track this catalyst
Indication
Advanced Biliary Tract Cancer(BTC)

Other upcoming events for GHRS

Phase 3 ReadoutPhase 3 Topline: A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy
Phase 2 StartPhase 2 Start: A Phase 1/2 Open-Label Intrathecal Administration of TSHA-105 to Determine the Safety and Efficacy i
Phase 2 StartPhase 2 Start: Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled
Phase 2 StartPhase 2 Start: MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination With Eithe
Phase 2 StartPhase 2 Start: A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Transl

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

  • 200 free AI credits / month to run live multi-agent analysis
  • Watchlist, catalyst alerts & the biotech event calendar
  • Full pipeline, financials & FDA data on every company
Start Free
    Phase 2 Start: A Phase II Study of Nivolumab Plus Relatlimab 360 mg/360 mg and Gemcitabine/Cisplatin as First-Line — GHRS Phase 2 Start | BioSniper